Clinical, Metabolic Factors Influence T2D Remission After Gastric Bypass
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
THURSDAY, July 6, 2023 -- Regardless of weight loss, a significant proportion of patients experience type 2 diabetes (T2D) remission after Roux-en-Y gastric bypass (RYGB), according to a study presented at the annual meeting of the American Society for Metabolic and Bariatric Surgery, held from June 25 to 29 in Las Vegas.
Karl Hage, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues evaluated T2D resolution rates and identified factors associated with remission following RYGB. The analysis included 705 adults with T2D undergoing RYGB between 2008 and 2017, with a mean follow-up of 6.3 years.
The researchers found that 49 percent of patients had T2D remission at the last follow-up visit. Factors predicting remission included preoperative duration of T2D, baseline hemoglobin A1C, insulin use prior to surgery, number of antidiabetic medications, and total body weight loss percentage. There was a proportional relationship observed between remission rates and total body weight loss percentage (quartile 1: 40.3 percent; quartile 2: 48.9 percent; quartile 3: 51.1 percent; quartile 4: 55.3 percent).
"This study shows that diabetes remission is not fully contingent on weight loss after gastric bypass surgery," a coauthor said in a statement. "The key is to maintain close monitoring and efficient management of diabetes after surgery. Metabolic surgery is not a magic pill, but it offers perhaps the only chance for many people to rid themselves of diabetes and its associated complications once and for all."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation
WEDNESDAY, May 29, 2024 -- Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor agonist discontinuation...
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 -- For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.